Search research articles
Contact Us
Filters
Showing results (421-430 of 467) with videos related to
Page
of 47
Sort By:
Blood Advances
|
November 21, 2022
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
Daniela Clerici, Laura Galli, Raffaella Greco, et al.
AIDS (London, England)
|
December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes
Amanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
The Lancet. HIV
|
November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
The Journal of Antimicrobial Chemotherapy
|
January 31, 2016
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen
Andrea De Luca, Philippe Flandre, David Dunn, et al.
HIV Medicine
|
March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
Dathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Disaster Medicine and Public Health Preparedness
|
July 28, 2020
Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan
Stefano Franchini, Marzia Spessot, Giovanni Landoni, et al.
International Journal of Epidemiology
|
April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration
, Charlotte Lewden, Vincent Bouteloup, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 22, 2025
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Anca Streinu-Cercel, Antonella Castagna, Shan-Chwen Chang, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Plos One
|
April 6, 2017
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
Fanny Chereau, Yoann Madec, Caroline Sabin, et al.
Page
of 47
Search research articles
Search
Showing results (421-430 of 467) with videos related to
Sort By:
Page
of 47
Blood Advances
|
November 21, 2022
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
Daniela Clerici, Laura Galli, Raffaella Greco, et al.
AIDS (London, England)
|
December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes
Amanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
The Lancet. HIV
|
November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
The Journal of Antimicrobial Chemotherapy
|
January 31, 2016
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen
Andrea De Luca, Philippe Flandre, David Dunn, et al.
HIV Medicine
|
March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
Dathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Disaster Medicine and Public Health Preparedness
|
July 28, 2020
Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan
Stefano Franchini, Marzia Spessot, Giovanni Landoni, et al.
International Journal of Epidemiology
|
April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration
, Charlotte Lewden, Vincent Bouteloup, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 22, 2025
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Anca Streinu-Cercel, Antonella Castagna, Shan-Chwen Chang, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Plos One
|
April 6, 2017
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
Fanny Chereau, Yoann Madec, Caroline Sabin, et al.
Page
of 47